Module

Outcomes After HBV Treatment Failure Due to Resistance

Source: Clinical Strategies for Preventing and Managing Resistance to Anti-HBV Agents

Outcomes After HBV Treatment Failure Due to Resistance

Faculty:
Daryl T-Y Lau, MD, MSc, MPH, FRCP(C)

CME CREDIT INFORMATION

Release Date: 04/14/06

Expiration Date: 04/13/07

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Review HBV resistance to lamivudine treatment
Discuss resistance to adefovir in the treatment of hepatitis B
Discuss entecavir use and resistance in chronic HBV infection

Topics covered include:

Hepatitis B Viral Resistance
Lamivudine Resistance and Natural History of Disease
Adefovir Resistance
Entecavir Resistance
Conclusion

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.